• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?

作者信息

Lenz Georg, Dreyling Martin

机构信息

Lymphoma Section, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany.

出版信息

Nat Clin Pract Oncol. 2005 Feb;2(2):72-3. doi: 10.1038/ncponc0077.

DOI:10.1038/ncponc0077
PMID:16264875
Abstract
摘要

相似文献

1
Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?
Nat Clin Pract Oncol. 2005 Feb;2(2):72-3. doi: 10.1038/ncponc0077.
2
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.高剂量序贯化疗及体内利妥昔单抗清除的干细胞自体移植治疗套细胞淋巴瘤：R-HDS方案的10年更新
Bone Marrow Transplant. 2009 Mar;43(6):509-11. doi: 10.1038/bmt.2008.349. Epub 2008 Oct 27.
3
Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.
Br J Haematol. 2005 Nov;131(3):338-40. doi: 10.1111/j.1365-2141.2005.05777.x.
4
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.环磷酰胺、长春新碱、阿霉素和强的松联合方案（CHOP）可提高缓解率，但不能延长生存期，且与米托蒽醌、苯丁酸氮芥和强的松联合方案（MCP）相比，在滤泡性和套细胞淋巴瘤中血液学毒性更低：德国低度淋巴瘤研究组一项前瞻性随机试验的结果
Cancer. 2006 Sep 1;107(5):1014-22. doi: 10.1002/cncr.22093.
5
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.利妥昔单抗对套细胞淋巴瘤自体干细胞移植后分子复发的抢先治疗。
J Clin Oncol. 2009 Sep 10;27(26):4365-70. doi: 10.1200/JCO.2008.21.3116. Epub 2009 Aug 3.
6
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.来那度胺与利妥昔单抗对套细胞淋巴瘤的体内外协同抗肿瘤作用
Am J Hematol. 2009 Sep;84(9):553-9. doi: 10.1002/ajh.21468.
7
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.大剂量阿糖胞苷联合放疗并进行自体移植挽救治疗R-CHOP方案敏感的套细胞淋巴瘤患者。
Br J Haematol. 2009 Feb;144(4):524-30. doi: 10.1111/j.1365-2141.2008.07498.x. Epub 2008 Nov 26.
8
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
Br J Haematol. 2010 Mar;148(5):810-2. doi: 10.1111/j.1365-2141.2009.07998.x. Epub 2009 Nov 16.
9
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.真核起始因子4E的表达可预测接受超CVAD和利妥昔单抗治疗、交替使用利妥昔单抗、大剂量甲氨蝶呤和阿糖胞苷的套细胞淋巴瘤患者的临床结局。
Cancer. 2009 Oct 15;115(20):4727-36. doi: 10.1002/cncr.24506.
10
Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma.
Haematologica. 2006 Mar;91(3):425-6.